What is Chardan Capital’s Estimate for CRSP FY2026 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Chardan Capital issued their FY2026 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, May 7th. Chardan Capital analyst Y. Livshits expects that the company will post earnings per share of ($3.97) for the year. Chardan Capital has a “Buy” rating and a $82.00 price target on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

A number of other equities research analysts also recently issued reports on the stock. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a research note on Wednesday, February 12th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, March 21st. Needham & Company LLC cut their target price on CRISPR Therapeutics from $84.00 to $81.00 and set a “buy” rating for the company in a research note on Wednesday. Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. Finally, Barclays dropped their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research report on Friday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $73.12.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $35.62 on Friday. The company has a market cap of $3.08 billion, a price-to-earnings ratio of -8.15 and a beta of 1.88. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The stock has a fifty day moving average price of $38.15 and a 200-day moving average price of $42.77.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. CRISPR Therapeutics’s revenue was up 71.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.43) earnings per share.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,381 shares of company stock worth $1,608,243. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CRSP. Costello Asset Management INC acquired a new position in shares of CRISPR Therapeutics during the 1st quarter valued at $27,000. Wood Tarver Financial Group LLC acquired a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $30,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth about $36,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $39,000. Finally, Western Pacific Wealth Management LP increased its position in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.